Current and emerging therapies for the treatment of myasthenia gravis
Renato Mantegazza, Silvia Bonanno, Giorgia Camera, Carlo AntozziDepartment of Neuromuscular Diseases and Neuroimmunology, Fondazione Istituto Neurologico Carlo Besta, Milan, ItalyAbstract: Myasthenia gravis (MG) is an autoimmmune disease in which autoantibodies to different antigens of the neuromusc...
Guardado en:
Autores principales: | Renato Mantegazza, Silvia Bonanno, Giorgia Camera, et al |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/42d9506f1cd747d1880b6e7e5e5b2e37 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Mycophenolate mofetil for myasthenia gravis: a clear and present controversy
por: Chad Heatwole, et al.
Publicado: (2008) -
Association Between Myasthenia Gravis and Memory: A Systematic Review and Meta-Analysis
por: Xiaoling Zhou, et al.
Publicado: (2021) -
Comorbid Autoimmune Diseases in Patients With Myasthenia Gravis: A Retrospective Cross-Sectional Study of a Chinese Cohort
por: Jianquan Shi, et al.
Publicado: (2021) -
Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study
por: Sijia Zhao, et al.
Publicado: (2021) -
Patients With Myasthenia Gravis With Acute Onset of Dyspnea: Predictors of Progression to Myasthenic Crisis and Prognosis
por: Yangyu Huang, et al.
Publicado: (2021)